Baxter International (BAX) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solventum (SOLV) has outperformed Baxter International (BAX) over the past year, gaining 19.0% versus a gain of 4.7%. Solventum is the larger company by market cap ($14.62 billion vs $12.39 billion), about 1.2 times the size, while Baxter International is growing revenue faster (+5.7% vs +0.9%). On valuation, Baxter International trades at a lower forward P/E (11.8x vs 11.9x for Solventum).
Baxter International pays a dividend yielding 0.83%, while Solventum does not currently pay one. Solventum converts more of its revenue into profit, with a net margin of 18.7% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BAX | SOLV |
|---|---|---|
| Share price | $23.97 | $85.88 |
| Market cap | $12.39B | $14.62B |
| 1-day change | -1.60% | -1.33% |
| YTD return | +25.43% | +8.38% |
| 1-year return | +4.67% | +19.01% |
| 5-year return | -69.92% | — |
| P/E ratio (TTM) | — | 10.51 |
| Forward P/E | 11.75 | 11.88 |
| EPS (TTM) | $-1.85 | $8.17 |
| Dividend yield | 0.83% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $11.24B | $8.32B |
| Revenue growth (YoY) | +5.72% | +0.86% |
| Net income (latest FY) | $-957.00M | $1.56B |
| Gross margin | 30.05% | 53.47% |
| Operating margin | -2.74% | 26.20% |
| Net margin | -8.51% | 18.69% |
| 52-week high | $30.00 | $94.16 |
| 52-week low | $15.73 | $62.38 |
| Distance from 52-week high | -20.10% | -8.79% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +16.48% | +9.82% |
| Average volume | 6.63M | 1.02M |
| Shares outstanding | 517.00M | 170.22M |
| Employees | 37,500 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SOLV has outperformed BAX by 14.3 percentage points over the past year.
- Solventum is more profitable, keeping 18.7 cents of every revenue dollar as net income versus -8.5 cents for Baxter International.
About Baxter International
BAX stock →Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Health Care · Medical/Dental Instruments · 37,500 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
BAX vs SOLV FAQ
Which is bigger, Baxter International or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.62B compared with $12.39B for Baxter International (BAX).
Which stock has performed better over the past year, BAX or SOLV?
SOLV returned +19.01% over the past 12 months, compared with +4.67% for BAX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Baxter International or Solventum?
Baxter International pays a dividend yielding 0.83%, while Solventum does not currently pay a regular dividend.
Are Baxter International and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.